Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients

BIOXYTRAN, INC

IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.
Trial will evaluate safety, efficacy, and pharmacokinetics of oral ProLectin-M; results to guide a 408-patient Phase III trial.
Condition: each site must obtain Ethics Committee approval before starting enrollment.
Press release issued December 8, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.